Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
BCR-ABL TKI (specialist)

Dasatinib

Brand names: Sprycel

Dasatinib is an oral tyrosine kinase inhibitor used by specialists in the treatment of chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia; it is a haemato-oncology drug rather than a rheumatology agent.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It potently inhibits BCR-ABL and SRC-family kinases, blocking the constitutive signalling that drives proliferation of leukaemic cells.

Prescribing in practice

  • Can cause fluid retention including pleural effusion and is associated with QT prolongation and myelosuppression — monitor closely and interrupt or reduce dose as needed.
  • Metabolised by CYP3A4, so avoid strong inducers and inhibitors and minimise drugs that prolong the QT interval.
  • A specialist haemato-oncology medicine; prescribe according to the SPC and treatment protocols.

Monitoring

Monitor full blood count, for signs of fluid retention, and ECG/electrolytes where QT-prolongation risk exists.

Counselling the patient

  • Report breathlessness, swelling or unexpected bruising and bleeding.
  • Take consistently with respect to food as directed and avoid grapefruit.
  • Seek urgent advice for fever or signs of infection.

Evidence & guidelines

Efficacy in chronic myeloid leukaemia is established by major randomised trials and NICE appraisals.

Reference: NICE TA425; BSH CML guidelines; ESMO; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways